Cargando…

BRCA mutation in ovarian cancer: testing, implications and treatment considerations

Ovarian cancer is a heterogeneous disease that encompasses a number of different cellular subtypes, the most common of which is high-grade serous ovarian cancer (HGSOC). Still today, ovarian cancer is primarily treated with chemotherapy and surgery. Recent advances in the hereditary understanding of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neff, Robert T., Senter, Leigha, Salani, Ritu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524247/ https://www.ncbi.nlm.nih.gov/pubmed/28794804 http://dx.doi.org/10.1177/1758834017714993

Ejemplares similares

BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations
por: Shah, Sidrah, et al.
Publicado: (2021)

Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations
por: Madariaga, Ainhoa, et al.
Publicado: (2019)

BRCA mutations in the manifestation and treatment of ovarian cancer
por: Pan, Zimin, et al.
Publicado: (2017)

Survival from breast cancer in women with a BRCA2 mutation by treatment
por: Evans, D. Gareth, et al.
Publicado: (2021)

Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
por: Kotsopoulos, Joanne, et al.
Publicado: (2012)

UK BRCA mutation testing in patients with ovarian cancer
por: George, Angela
Publicado: (2015)

International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation
por: Metcalfe, Kelly, et al.
Publicado: (2019)

BRCA germline mutation test for all woman with ovarian cancer?
por: Paradiso, A. V., et al.
Publicado: (2019)

BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside
por: Boussios, Stergios, et al.
Publicado: (2022)

Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer
por: Hollis, Robert L, et al.
Publicado: (2017)

Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review
por: Bougie, O., et al.
Publicado: (2011)

Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
por: Lorusso, Domenica, et al.
Publicado: (2018)

Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control
por: Janavičius, Ramūnas
Publicado: (2010)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients
por: Manchana, Tarinee, et al.
Publicado: (2020)

Uptake of Family-Specific Mutation Genetic Testing Among Relatives of Patients with Ovarian Cancer with BRCA1 or BRCA2 Mutation
por: Jeong, Go Woon, et al.
Publicado: (2021)

BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications
por: Messina, Carlo, et al.
Publicado: (2020)

Reliability of Tumor Testing Compared to Germline Testing for Detecting BRCA1 and BRCA2 Mutations in Patients with Epithelial Ovarian Cancer
por: Bekos, Christine, et al.
Publicado: (2021)

Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location
por: Sekine, Masayuki, et al.
Publicado: (2021)

BRCA Mutations—The Achilles Heel of Breast, Ovarian and Other Epithelial Cancers
por: Loboda, Anna P., et al.
Publicado: (2023)

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
por: Iqbal, J, et al.
Publicado: (2012)

Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations
por: Birkbak, Nicolai Juul, et al.
Publicado: (2013)

Practice guidelines for BRCA1/2 tumour testing in ovarian cancer
por: Grafodatskaya, Daria, et al.
Publicado: (2022)

Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers
por: Arakelyan, Arsen, et al.
Publicado: (2021)

Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome
por: Ashour, Mohamed, et al.
Publicado: (2019)

Mutations in BRCA1, BRCA2 and other breast and ovarian cancer susceptibility genes in Central and South American populations
por: Jara, Lilian, et al.
Publicado: (2017)

Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting
por: Maiorano, Mauro Francesco Pio, et al.
Publicado: (2023)

Pathogenesis and New Therapeutic Targets of Ovarian Cancer
por: Shih, Ie-Ming, et al.
Publicado: (2012)

BRCA1 founder mutations and ovarian cancer in Belarus
por: Savanevich, A, et al.
Publicado: (2015)

BRCA mutation in high grade epithelial ovarian cancers
por: Manchana, Tarinee, et al.
Publicado: (2019)

The BRCA Gene in Epithelial Ovarian Cancer
por: Sánchez-Lorenzo, Luisa, et al.
Publicado: (2022)

Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil
por: Maistro, Simone, et al.
Publicado: (2016)

BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update
por: Savanevich, Alena, et al.
Publicado: (2021)

Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
por: Zaaijer, Leendert H, et al.
Publicado: (2016)

Epitope-positive truncating MLH1 mutation and loss of PMS2: implications for IHC-directed genetic testing for lynch syndrome
por: Zighelboim, Israel, et al.
Publicado: (2009)

The Impact of BRCA1- and BRCA2 Mutations on Ovarian Reserve Status
por: C.E, Drechsel Katja, et al.
Publicado: (2022)

Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status
por: Gadducci, Angiolo, et al.
Publicado: (2019)

Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision
por: Lewis, Kelsey E., et al.
Publicado: (2018)

Cost-effective BRCA Testing in Advanced Ovarian Cancer
por: Kim, Myungshin
Publicado: (2023)

Combined Tumor-Based BRCA1/2 and TP53 Mutation Testing in Ovarian Cancer
por: Borcoman, Edith, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_seh1io58g5mhcc44vou1h8jbiv